The US Food and Drug Administration (FDA)
is notifying healthcare professionals that histoplasmosis and other invasive
fungal infections are not consistently recognised in
patients taking tumor necrosis factor-alpha blockers (TNF blockers),
certolizumab pegol (Cimzia), etanercept (Enbrel), adalimumab (Humira), and infliximab (Remicade).
This has resulted in delays in appropriate treatment, sometimes resulting in death.
The FDA has received reports of patients developing pulmonary and disseminated
histoplasmosis, coccidioidomycosis, blastomycosis and other opportunistic infections while taking TNF blockers.
(όλο το άρθρο στο http://www.docguide.com
